-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Reviewing Alpha Tau Medical (NASDAQ:DRTS) and Nephros (NASDAQ:NEPH)
Reviewing Alpha Tau Medical (NASDAQ:DRTS) and Nephros (NASDAQ:NEPH)
Alpha Tau Medical (NASDAQ:DRTS – Get Rating) and Nephros (NASDAQ:NEPH – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation and institutional ownership.
Profitability
This table compares Alpha Tau Medical and Nephros' net margins, return on equity and return on assets.
Get Alpha Tau Medical alerts:Net Margins | Return on Equity | Return on Assets | |
Alpha Tau Medical | N/A | -49.72% | -33.76% |
Nephros | -71.25% | -42.99% | -36.30% |
Volatility and Risk
Alpha Tau Medical has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500. Comparatively, Nephros has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500.
Earnings and Valuation
This table compares Alpha Tau Medical and Nephros' revenue, earnings per share and valuation.Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Alpha Tau Medical | N/A | N/A | -$27.27 million | N/A | N/A |
Nephros | $10.32 million | 1.16 | -$4.11 million | ($0.74) | -1.57 |
Nephros has higher revenue and earnings than Alpha Tau Medical.
Analyst Ratings
This is a summary of recent ratings for Alpha Tau Medical and Nephros, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Alpha Tau Medical | 0 | 0 | 3 | 0 | 3.00 |
Nephros | 0 | 1 | 1 | 0 | 2.50 |
Alpha Tau Medical currently has a consensus price target of $17.67, suggesting a potential upside of 378.77%. Nephros has a consensus price target of $5.25, suggesting a potential upside of 352.59%. Given Alpha Tau Medical's stronger consensus rating and higher possible upside, equities analysts clearly believe Alpha Tau Medical is more favorable than Nephros.
Insider and Institutional Ownership
1.0% of Alpha Tau Medical shares are owned by institutional investors. Comparatively, 42.1% of Nephros shares are owned by institutional investors. 39.5% of Alpha Tau Medical shares are owned by company insiders. Comparatively, 8.6% of Nephros shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Alpha Tau Medical beats Nephros on 6 of the 11 factors compared between the two stocks.
About Alpha Tau Medical
(Get Rating)
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
About Nephros
(Get Rating)
Nephros, Inc. is a medical device company, which engages in developing and selling liquid purification filters and an on-line mid dilution hemodiafiltration system. The company operates in two segments: Water Filtration, Pathogen Detection and Renal Products. The Water Filtration segment includes both the medical device and commercial filtration product lines. The Pathogen Detection segment develops and sells portable, real-time water testing systems designed to provide actionable data on waterborne pathogens in approximately one hour. The Renal Products segment consists of SRP, which is focused on the development of medical device products for patients with renal disease, including a second-generation HDF system for the treatment of patients with ESRD. Its ultrafilters are used in dialysis centers for the removal of biological contaminants from water, bicarbonate concentrate, and blood. The company was founded on April 3, 1997 and is headquartered in South Orange, NJ.
Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.
Alpha Tau Medical (NASDAQ:DRTS – Get Rating) and Nephros (NASDAQ:NEPH – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation and institutional ownership.
Alpha Tau Medical(纳斯达克股票代码:DRTS — 获取评级)和Nephros(纳斯达克股票代码:NEPH — 获取评级)都是小型医疗公司,但哪家业务更好?我们将根据分析师建议的强度、股息、盈利能力、风险、收益、估值和机构所有权对比这两家企业。
Profitability
盈利能力
This table compares Alpha Tau Medical and Nephros' net margins, return on equity and return on assets.
该表比较了Alpha Tau Medical和Nephros的净利润率、股本回报率和资产回报率。
Net Margins | Return on Equity | Return on Assets | |
Alpha Tau Medical | N/A | -49.72% | -33.76% |
Nephros | -71.25% | -42.99% | -36.30% |
净利润 | 股本回报率 | 资产回报率 | |
阿尔法泰医疗 | 不适用 | -49.72% | -33.76% |
内弗罗斯 | -71.25% | -42.99% | -36.30% |
Volatility and Risk
波动性和风险
Alpha Tau Medical has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500. Comparatively, Nephros has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500.
Alpha Tau Medical的beta值为1.01,这意味着其股价的波动性比标准普尔500指数高1%。相比之下,Nephros的beta值为1.23,这意味着其股价的波动性比标准普尔500指数高23%。
Earnings and Valuation
收益和估值
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Alpha Tau Medical | N/A | N/A | -$27.27 million | N/A | N/A |
Nephros | $10.32 million | 1.16 | -$4.11 million | ($0.74) | -1.57 |
总收入 | 价格/销售比率 | 净收入 | 每股收益 | 市盈率 | |
阿尔法泰医疗 | 不适用 | 不适用 | -2727 万美元 | 不适用 | 不适用 |
内弗罗斯 | 1,032 万美元 | 1.16 | -411 万美元 | (0.74 美元) | -1.57 |
Nephros has higher revenue and earnings than Alpha Tau Medical.
Nephros 的收入和收入高于 Alpha Tau Medical
Analyst Ratings
分析师评级
This is a summary of recent ratings for Alpha Tau Medical and Nephros, as reported by MarketBeat.
据MarketBeat报道,这是Alpha Tau Medical和Nephros最近评级的摘要。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Alpha Tau Medical | 0 | 0 | 3 | 0 | 3.00 |
Nephros | 0 | 1 | 1 | 0 | 2.50 |
卖出评级 | 保持收视率 | 买入评级 | 强劲的买入评级 | 评分分数 | |
阿尔法泰医疗 | 0 | 0 | 3 | 0 | 3.00 |
内弗罗斯 | 0 | 1 | 1 | 0 | 2.50 |
Alpha Tau Medical currently has a consensus price target of $17.67, suggesting a potential upside of 378.77%. Nephros has a consensus price target of $5.25, suggesting a potential upside of 352.59%. Given Alpha Tau Medical's stronger consensus rating and higher possible upside, equities analysts clearly believe Alpha Tau Medical is more favorable than Nephros.
Alpha Tau Medical目前的共识目标价为17.67美元,这表明潜在的上涨空间为378.77%。Nephros的共识目标价为5.25美元,表明潜在的上涨空间为352.59%。鉴于Alpha Tau Medical更强的共识评级和更高的上行空间,股票分析师显然认为Alpha Tau Medical比Nephros更有利。
Insider and Institutional Ownership
内部所有权和机构所有权
1.0% of Alpha Tau Medical shares are owned by institutional investors. Comparatively, 42.1% of Nephros shares are owned by institutional investors. 39.5% of Alpha Tau Medical shares are owned by company insiders. Comparatively, 8.6% of Nephros shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Alpha Tau Medical的1.0%股份由机构投资者持有。相比之下,Nephros的股份有42.1%由机构投资者持有。Alpha Tau Medical的39.5%的股份由公司内部人士持有。相比之下,8.6%的Nephros股份由公司内部人士拥有。强大的机构所有权表明,对冲基金、捐赠基金和大型基金经理认为一家公司已为长期增长做好了准备。
Summary
摘要
Alpha Tau Medical beats Nephros on 6 of the 11 factors compared between the two stocks.
与两只股票相比,Alpha Tau Medical在11个因素中的6个因素上击败了Nephros。
About Alpha Tau Medical
关于 Alpha Tau
(Get Rating)
(获取评分)
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
Alpha Tau Medical Ltd. 是一家临床阶段的肿瘤治疗公司,在以色列和美国从事用于治疗实体癌的弥散α-发射体放射疗法(Alpha DarT)的研究、开发和商业化。其 Alpha-DART 技术用于皮肤癌、口腔癌、胰腺癌和乳腺癌的临床试验;以及肝细胞癌、多形胶质母细胞瘤、肺癌等的临床前研究。该公司成立于2015年,总部位于以色列耶路撒冷。
About Nephros
关于 Nepros
(Get Rating)
(获取评分)
Nephros, Inc. is a medical device company, which engages in developing and selling liquid purification filters and an on-line mid dilution hemodiafiltration system. The company operates in two segments: Water Filtration, Pathogen Detection and Renal Products. The Water Filtration segment includes both the medical device and commercial filtration product lines. The Pathogen Detection segment develops and sells portable, real-time water testing systems designed to provide actionable data on waterborne pathogens in approximately one hour. The Renal Products segment consists of SRP, which is focused on the development of medical device products for patients with renal disease, including a second-generation HDF system for the treatment of patients with ESRD. Its ultrafilters are used in dialysis centers for the removal of biological contaminants from water, bicarbonate concentrate, and blood. The company was founded on April 3, 1997 and is headquartered in South Orange, NJ.
Nephros, Inc. 是一家医疗器械公司,从事液体净化过滤器和在线中度稀释血液透析过滤系统的开发和销售。该公司分为两个部门:水过滤、病原体检测和肾脏产品。水过滤部门包括医疗设备和商用过滤产品线。病原体检测部门开发和销售便携式实时水质测试系统,旨在在大约一小时内提供有关水传播病原体的可操作数据。肾脏产品部门由SRP组成,SRP专注于为肾脏疾病患者开发医疗器械产品,包括用于治疗ESRD患者的第二代HDF系统。它的超滤器用于透析中心,用于去除水、碳酸氢盐浓缩物和血液中的生物污染物。该公司成立于1997年4月3日,总部位于新泽西州南奥兰治。
Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Alpha Tau 医学日报的新闻和评级 -在下面输入您的电子邮件地址,通过Marketbeat.com的免费每日电子邮件时事通讯接收Alpha Tau Medical及相关公司的最新新闻和分析师评级的简明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧